Tuoyi
(Camrelizumab)Phase 3Monoclonal antibody
Camrelizumab is used to treat certain types of cancer, including lung cancer and lymphoma, by helping the immune system recognize and attack cancer cells.[1] Tuoyi is currently being investigated across 46 indications[3], with its most advanced program in Phase 3.[1]
Tuoyi is one of 864 small molecule programs targeting Gastric Cancer. It is currently in Phase 3.
46
Indications
227
Total Trials
84
Active Trials
863
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 46 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tuoyi
SSun Yat-sen University
Phase 3
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q4 2026
Recruiting
Gastric Cancer
NCT06485271
Phase 1/2Recruiting
Efficacy and Safety
NCT04481763
Phase 1/2Active, not recruiting
Esophageal Carcinoma
NCT05176002
Phase 2Not yet recruiting
First-Line Treatment
NCT06694324
Not yet recruiting
Esophageal Cancer
NCT04616040
Phase 1Recruiting
Pancreatic Cancer
NCT06326736
Clinical
Trials by Indication[1]
Gastric Cancer18 trials
A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer
Recruiting·—··NCT06485271·504 enrolled
Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer
Unknown status·—·Phase 2·NCT04367025·70 enrolled
Show 15 more trials
Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer
Unknown status·TThe First Affiliated Hospital of Xiamen University·Phase 1/2·NCT04572542·46 enrolled
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
Active, not recruiting·TThe Second Affiliated Hospital of Fujian Medical University·Phase 2·NCT05602935·29 enrolled
Hepatocellular Carcinoma17 trials
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 3·NCT05613478·130 enrolled
Show 14 more trials
A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin
Unknown status·—·Phase 2·NCT04850040·15 enrolled
Breast Cancer11 trials
Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2/3·NCT04907344·420 enrolled
Show 8 more trials
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1/2·NCT05981001·170 enrolled
Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer
Completed·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04805736·60 enrolled
Nasopharyngeal Carcinoma10 trials
Show 7 more trials
Camrelizumab10 trials
Show 7 more trials
A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04303741·46 enrolled
65 more indications
Non-Small Cell Lung Cancer8 trials
A Real World Study of β2-Adrenergic Blocker Plus PD-1 Inhibitor in Non-Small Cell Lung Cancer
Completed·—··NCT05387512·59 enrolled
Show 5 more trials
Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04828395·65 enrolled
Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer
Active, not recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT04379739·89 enrolled
Lymphoma7 trials
Show 4 more trials
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
Recruiting·—·Phase 1/2·NCT06376721·43 enrolled
Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma
Unknown status·—·Phase 2·NCT04233294·100 enrolled
Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor
Recruiting·—·Phase 1/2·NCT04337606·100 enrolled
Esophageal Squamous Cell Carcinoma7 trials
Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05637268·23 enrolled
Show 4 more trials
Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05476380·39 enrolled
First-line Treatment6 trials
Esophageal Cancer6 trials
Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer
Unknown status·TThe First Affiliated Hospital of Henan University of Science and Technology·Phase 2·NCT04390945·62 enrolled
Show 3 more trials
Colorectal Cancer5 trials
Pancreatic Cancer5 trials
Show 2 more trials
Cervical Cancer5 trials
Show 2 more trials
Triple-Negative Breast Cancer5 trials
Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer
Not yet recruiting·—·Phase 2·NCT07107217·40 enrolled
Efficacy and Safety4 trials
Show 1 more trial
Head and Neck Squamous Cell Carcinoma4 trials
Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma
Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT04440917·32 enrolled
Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
Unknown status·—·Phase 2·NCT06170697·46 enrolled
Melanoma3 trials
Concurrent Chemoradiotherapy3 trials
Esophageal Carcinoma2 trials
Advanced2 trials
Advanced Solid Tumor2 trials
Oral Squamous Cell Carcinoma2 trials
Neoadjuvant Chemoimmunotherapy2 trials
Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC
Not yet recruiting·NNational Medical Research Radiological Centre of the Ministry of Health of Russia·Phase 2·NCT07400094·50 enrolled
Ovarian Cancer2 trials
Adenocarcinoma2 trials
Osteosarcoma2 trials
Intrahepatic Cholangiocarcinoma2 trials
Treatment2 trials
Esophageal Squamous Cell Cancer2 trials
Biliary Tract Cancer2 trials
Metastatic Colorectal Cancer2 trials
Immunotherapy2 trials
Chemoradiation1 trial
The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
Recruiting·—·Phase 2·NCT05213884·30 enrolled
Cholangiocarcinoma1 trial
Second-line Treatment1 trial
Brain Metastases1 trial
Induction Chemotherapy1 trial
First Line Therapy1 trial
Acute Myeloid Leukemia1 trial
Neoadjuvant Therapy1 trial
Gastric Adenocarcinoma1 trial
Refractory Solid Tumors1 trial
Cutaneous Squamous Cell Carcinoma1 trial
Chemoradiotherapy1 trial
Ovarian Clear Cell Carcinoma1 trial
Stereotactic Body Radiotherapy1 trial
The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC
Recruiting·—·Phase 2·NCT04830267·39 enrolled
Advanced or Metastatic NSCLC1 trial
Endometrial Cancer1 trial
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Recruiting·—·Phase 2·NCT06413992·117 enrolled
Anti-PD-1 Antibody1 trial
Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma
Unknown status·—·Phase 2·NCT05461235·1 enrolled
Locally-advanced Rectal Cancer1 trial
Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer
Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1/2·NCT04231552·30 enrolled
Non-squamous NSCLC1 trial
Pancreatic Carcinoma1 trial
Gastrointestinal1 trial
Lung Cancer1 trial
Pancreatic Adenocarcinoma1 trial
Hypopharyngeal Carcinoma1 trial
Adrenocortical Carcinoma1 trial
Central Nervous System Lymphoma1 trial
Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Recruiting·—·Phase 2·NCT04070040·21 enrolled
Nab-paclitaxel1 trial
A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06632405·60 enrolled
Adrenal Cortical Carcinoma1 trial
Neoadjuvant Chemotherapy1 trial
Adjuvant Treatment1 trial
Adjuvant Chemotherapy1 trial
Locally Advanced Head and Neck Cancer1 trial
Neuroendocrine Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Camrelizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Programmed Cell Death Protein 1 Antagonist[2]
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- SSun Yat-sen University